7480 Federal Register / Vol. 62, No. 33 / Wednesday, February 19, 1997 / Notices

Week of February 17

Tuesday, February 18

1:00 p.m.

Briefing on BPR Project on

Redesigned Materials Licensing

Process (Public Meeting)

(Contact: Don Cool, 301–415–7197)

2:30 p.m.

Briefing on Analysis of Quantifying

Plant Watch List Indicators (Arthur

Andersen Study) (Public Meeting)

(Contact: Rick Barrett, 301–415–7482)

4:00 p.m.

Discussion of Interagency Issues

(Closed—Ex. 9)

Wednesday, February 19

2:00 p.m.

Briefing on Millstone and Marine

Yankee Lessons Learned (Public

Meeting)

(Contact: Steve Stein, 301–415–1296)

3:30 p.m.

Affirmation Session (Public Meeting)

(if needed)

Thursday, February 20

2:00 p.m.

Briefing on EEO Program (Public

Meeting)

(Contact: Ed Tucker, 301–415–7382)

Week of February 24—Tentative

Wednesday, February 26

11:30 a.m.

Affirmation Session (Public Meeting)

(if needed)

Week of March 3—Tentative

There are no meetings scheduled for

the Week of March 3.

Week of March 10—Tentative

Monday, March 10—Tentative

2:30 p.m.

Briefing on Implementation of

Maintenance Rule, Revised

Regulatory Guide, and

Consequences (Public Meeting)

Thrusday, March 13—Tentative

11:30 p.m.

Affirmation Session (Public Meeting)

(if needed)

The schedule for Commission

Meetings is subject to change on short

notice. To verify the status of meetings

call (recording)—(301) 415–1292.

Contact person for more information:

Bill Hill (301) 415–1661.

* * * * *

ADDITIONAL INFORMATION:

By a vote of 5–0 on February 11, the

Commission determined pursuant to

U.S.C. 552b(e) and 10 CFR Sec. 9.107(a)

of the Commission’s rules that ‘‘Meeting

with Republic of Korea National

Assembly Delegation (Closed—Ex. 9)’’

be held on February 11, and on less than

one week’s notice to the public.

By a vote of 4–0 on February 13, the

Commission determined pursuant to

U.S.C. 552b(e) and 10 CFR Sec. 9.107(a)

of the Commission’s rules that

‘‘Affirmation of Louisiana Energy

Services (Claiborne Enrichment Center);

Atomic Safety and Licensing Board

Partial Initial Decision (Resolving

Contentions J.4, K, and Q), LBP–96–25’’

be held on February 13, and on less than

one week’s notice to the public.

* * * * *

The NRC Commission Meeting

Schedule can be found on the Internet

at: http://www.nrc.gov/SECY/smj/

schedule.htm.

This notice is distributed by mail to

several hundred subscribers; if you no

longer wish to receive it, or would like

to be added to it, please contact the

Office of the Secretary, Attn: Operations

Branch, Washington, D.C. 20555 (301–

415–1661).

In addition, distribution of this

meeting notice over the internet system

is available. If you are interested in

receiving this Commission meeting

schedule electronically, please send an

electronic message to wmh.@nrc.gov or

dkw@nrc.gov.

* * * * *

Dated: February 14, 1997.

William M. Hill, Jr.,

SECY Tracking Officer, Office of the

Secretary.

[FR Doc. 97–4218 Filed 2–14–97; 2:05 pm]

BILLING CODE 7590–01–M

PRESIDENTIAL ADVISORY

COMMITTEE ON GULF WAR

VETERANS’ ILLNESSES

Meeting

AGENCY: Presidential Advisory

Committee on Gulf War Veterans’

Illnesses.

ACTION: Notice of open meeting.

SUMMARY: Under the provisions of the

Federal Advisory Committee Act, this

notice is hereby given to announce an

open meeting of the Presidential

Advisory Committee on Gulf War

Veterans’ Illnesses.

DATES: March 18, 1997, 8:30 a.m.-3:30

p.m.

PLACE: Wyndham Hotel, 215 W. South

Temple, Salt Lake City, UT 84101.

SUPPLEMENTARY INFORMATION: The

President established the Presidential

Advisory Committee on Gulf War

Veterans’ Illnesses by Executive Order

12961, May 26, 1995, and extended its

tenure by Executive Order 13034,

January 30, 1997. The purpose of this

committee is to review and provide

recommendations on the government’s

investigation of possible chemical and

biological weapons exposure incidents

during the Gulf War and on

implementation of the Committee’s

prior recommendations. The committee

reports to the President through the

Secretary of Defense, and Secretary of

Health and Human Services, and the

Secretary of Veterans Affairs. The

committee members have expertise

relevant to the functions of the

committee and are appointed by the

President from non-Federal sectors.

Tentative Agenda

Tuesday, March 18, 1997

8:30 a.m. Call to order and opening

remarks

8:35 a.m. Committee and staff

discussion of charge

8:50 a.m. Public comment

10:00 a.m. Break

10:15 a.m. Committee and staff

discussion: Implementation plan for

Final Report recommendations

10:30 a.m. Briefings: Overview of

ongoing and new DOD activities

11:10 a.m. Briefings: Status of DOD’s

chemical and biological warfare

agent case investigations

11:50 a.m. Briefings: Activities related

to Khamisiyah

12:30 p.m. Lunch

1:30 p.m. Briefings: Activities related to

Khamisiyah (cont.)

3:15 p.m. Committee and staff

discussion: Next steps

3:30 p.m. Meeting adjourned

A final agenda will be available at the

meeting.

Public Participation

The meeting is open to the public.

Members of the public who wish to

make oral statements should contact the

Advisory Committee at the address or

telephone number listed below at least

five business days prior to the meeting.

Reasonable provisions will be made to

include on the agenda presentations

from individuals who have not yet had

an opportunity to address the Advisory

Committee. Priority will be given to

Gulf War veterans whose accounts of

firsthand experience with chemical and

biological warfare agent detections

previously have not been conveyed to

the Committee. The Advisory

Committee Chair is empowered to

conduct the meeting in a fashion that

will facilitate the orderly conduct of

business. People who wish to file

written statements with the Advisory

Committee may do so at any time.
Federal Register / Vol. 62, No. 33 / Wednesday, February 19, 1997 / Notices 7481

1The Fund changed its name from foreign Fund,

Inc. on January 2, 1997.

2The Adviser changed its name from BZW

Barclays Global Fund Advisors on October 15,

1996.

3Shares of the Series (‘‘World Equity Benchmark

Shares’’ or ‘‘WEBS’’) are issued only in large

aggregations of WEBS known as ‘‘Creation Units.’’

WEBS are neither offered nor redeemed by the

Series in less than Creation Unit aggregations, but

WEBS may be bought or sold in smaller

aggregations in the secondary market on the

American Stock Exchange, were WEBS are listed

and traded. Additional Series are expected to be

added from time to time, and would be subject to

the requested order.

4The Custodian is not an affiliated person of

either the Fund or the Adviser.

5The Series will engage in hold-in-custody

repurchase agreements (i.e., repurchase agreements

where the counterpart or one of its affiliated

persons may have possession of, or control over, the

collateral subject to the agreement) only when cash

is received very late in the business day and

otherwise would be unavailable for investment.

FOR FURTHER INFORMATION CONTACT:

Michael E. Kowalok, Presidential

Advisory Committee on Gulf War

Veterans’ Illnesses, 1411 K Street, NW.,

suite 1000, Washington, DC 20005,

Telephone: (202) 761–0066, Fax: (202)

761–0310.

Dated: February 13, 1997.

C.A. Bock,

Federal Register Liaison Officer, Presidential

Advisory Committee on Gulf War Veterans’

Illnesses.

[FR Doc. 97–4043 Filed 2–18–97; 8:45 am]

BILLING CODE 3610–76–M

SECURITIES AND EXCHANGE

COMMISSION

[Investment Company Act Rel. No. 22507;

812–10334]

WEBS Index Fund, Inc., et al; Notice of

Application

February 12, 1997.

AGENCY: Securities and Exchange

Commission (’’SEC’’).

ACTION: Notice of application for

exemption Under the Investment

Company Act of 1940 (‘‘Act’’).

APPLICANTS: WEBS Index Fund, Inc. (the

‘‘Fund’’) 1 and Barclays Global Fund

Advisors (the ‘‘Adviser’’) 2.

RELEVANT ACT SECTIONS: Order requested

under section 17(d) of the Act and rule

17d–1 thereunder.

SUMMARY OF APPLICATION: Applicants

seek an order that would permit the

series of the fund to pool some or all of

their uninvested cash balances and the

cash collateral they receive in

connection with securities lending

activities (‘‘Cash Collateral’’) in one or

more joint accounts (‘‘Joint Accounts’’)

that invest in certain short-term high

quality debt securities (‘‘Short-Term

Investments’’)

FILING DATES: The application was filed

on September 13, 1996, and amended

on December 27, 1996. Applicants have

agreed to file an additional amendment

during the notice period, the substance

of which is incorporated herein.

HEARING OR NOTIFICATION OF HEARING: An

order granting the application will be

issued unless the SEC orders a hearing.

Interested persons may request a

hearing by writing to the SEC’s

Secretary and serving applicants with a

copy of the request, personally or by

mail. Hearing requests should be

received by the SEC by 5:30 p.m. on

March 10, 1997 and should be

accompanied by proof of service on

applicants, in the form of an affidavit or,

for lawyers, a certificate of service.

Hearing requests should state the nature

of the writer’s interest, the reason for the

request, and the issues contested.

Persons who wish to be notified of a

hearing may request such notification

by writing to the SEC’s Secretary.

ADDRESSES: Secretary, SEC, 450 Fifth

Street, N.W., Washington, D.C. 20549.

Applicants: WEBS Index Fund, Inc.,

c/o PFPC, Inc., 400 Bellevue Parkway,

Wilmington, Delaware 19809; BZW

Barclays Global Fund Advisors, 45

Fremont Street, San Francisco,

California 94105.

FOR FURTHER INFORMATION CONTACT:

Courtney S. Thornton, Senior Counsel,

at (202) 942–0583, or Mary Kay Ferch,

Branch Chief, at (202) 942–0564

(Division of Investment Management,

Office of Investment Company

Regulation).

SUPPLEMENTARY INFORMATION: The

following is a summary of the

application. The complete application

may be obtained for a fee from the SEC’s

Public Reference Branch.

Applicants’ Representatives

1. The Fund, a Maryland corporation,

is an open-end management investment

company that currently offers seventeen

series (the ‘‘Series’’).3 The Adviser

provides investment advisory services

for all of the Series.

2. The investment objective of each of

the Series is to provide investment

results that correspond generally to the

aggregate price and yield performance of

publicly traded securities in particular

markets, as represented by foreign

equity securities indexes compiled by

Morgan Stanley Capital International

(each, an ‘‘MSCI Index’’). Each Series

seeks to remain fully invested in a pool

of equity securities the performance of

which approximates that of the relevant

MSCI Index. In addition, each Series

may lend its portfolio securities to

approved brokers, dealers, and other

financial institutions. The Custodian

serves as the lending agent of the Fund

and, in that capacity, will share with the

respective Series any net income earned

on invested Cash Collateral in the

proportion agreed between the

Custodian and the Series from time to

time.4

3. Subject to guidelines adopted by

the board of directors of the Fund (the

‘‘Board’’) and such additional limits as

may be established by the Adviser, each

Series may invest uncommitted cash

balances and Cash Collateral

temporarily in the following Short-Term

Investments: (a) Obligations of the U.S.

Government and its agencies and

instrumentalities; (b) commercial paper

rated Prime-1 by Moody’s Investors

Services, Inc. or A–1 by Standard &

Poor’s Corporation (‘‘Commercial

Paper’’); (c) bank certificates of deposit

and bankers’ acceptances; (d)

repurchase agreements collateralized by

the foregoing securities;5 (e)

participation interests in such

securities; and (f) shares of unaffiliated

money market funds (subject to

applicable limits under the Act). The

maximum possible maturity of each

type of Short-Term Investment (other

than shares of money market funds) will

be 397 calendar days.

4. Applicants believe that the separate

purchase of Short-Term Investments by

each Series could result in certain

inefficiencies, a limitation on the return

that the Series could otherwise achieve,

and increased costs. Accordingly,

applicants propose to deposit the Series’

available cash balances in Joint

Accounts and to invest the daily balance

of the Joint Accounts in Short-Term

Investments. Applicants also propose to

deposit the Series’ Cash Collateral in a

separate Joint Account for investment in

Short-Term Investments selected by the

Adviser. The sole purpose of these Joint

Accounts would be to provide a

convenient means of aggregating what

otherwise would be daily transactions

for some or all of the Series to manage

their daily account balances.

5. The Adviser will not participate

monetarily in the Joint Accounts, nor

will it receive an additional fee for the

administration of the Accounts. The

Adviser will be responsible for directing

the investment of funds held by the

Joint Accounts, establishing accounting

and control procedures, operating the

Joint Accounts in accordance with

established procedures, and ensuring

the fair treatment of each Series. The